Development of o-aminobenzamide salt derivatives for improving water solubility and anti-undifferentiated gastric cancer

Li, Shuang; He, Yong; Li, Xuelin; Xiong, Yongxia; Peng, Ying; Wang, Cheng-Kun; Zhuo, Linsheng; Jiang, Weifan; Lu, Xianzhou; Wang, Zhen

doi:10.3389/fphar.2023.1118397

Cited by 1 publication

(1 citation statement)

References 29 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical management of GC is not satisfactory nowadays, and existing medicinal products including perbrolizumab, ramucirumab and apatinib have relatively serious side effects such as heart dysfunction, blood toxicity and certain liver and kidney function damage [ 3 ]. GC poses great threat to patients’ health and life quality, and even reduces their life expectancy, raising the cost of health care and the financial burden on families and societies [ 4 ]. Hence, early identification of patients at high risk of GC is essential and vital.…”

Section: Introductionmentioning

confidence: 99%

Unravelling diagnostic clusters and immune landscapes of disulfidptosis patterns in gastric cancer through bioinformatic assay

Zhang,

Chen,

Lin

et al. 2023

Aging

View full text Add to dashboard Cite

Disulfidptosis is a novel type of cell death mediated by SLC7A11-induced disulfide stress. Gastric cancer (GC) is a common malignant gastrointestinal tumor. Existing evidence shows that SLC7A11 can regulate cell death and improve the progression of GC, suggesting disulfidptosis may exist in the pathological process of GC. However, the underlying functions of disulfidptosis regulators in GC remain unknown. The dataset of GSE54129 was screened to comprehensively investigate the disulfidptosis-related diagnostic clusters and immune landscapes in GC. Totally 15 significant disulfidptosis regulators were identified via difference analysis between GC samples and controls. Then random forest model was utilized to assess their importance score (mean decrease Gini). Then a nomogram model was constructed, which could offer benefit to patients based on our subsequent decision curve analysis. All the included GC patients were divided into 2 disulfidptosis subgroups (clusterA and clusterB) according to the significant disulfidptosis regulators in virtue of consensus clustering analysis. The disulfidptosis score of each sample was calculated through PCA algorithms to quantify the disulfidptosis subtypes. Patients from clusterB exhibited lower disulfidptosis scores than those of patients in clusterA. In addition, we found that the cases in clusterB were closely associated with the immunity of activated CD4 T cell, etc., while clusterA was linked to immature dendritic cell, mast cell, natural killer T cell, natural killer cell, etc., which has a higher disulfidptosis score. Therefore, disulfidptosis regulators play an important role in the pathological process of GC, providing a promising marker and an immunotherapeutic strategy for future GC therapy.

show abstract

Section: Introductionmentioning

confidence: 99%